Xiaohan Hao

Internet-of-Things (IoT) are increasingly operating in the zero-trust environments where any devices and systems may be compromised and hence untrusted. In addition, data collected by and sent from IoT devices may be shared with and processed by edge computing systems, in order to reduce the reliance on centralized (cloud) servers, leading to further security and privacy issues. To cope with these challenges, this paper proposes an innovative blockchain-enabled information sharing solution in zero-trust context to guarantee anonymity yet entity authentication, data privacy yet data trustworthiness, and participant stimulation yet fairness. This new solution is able to support filtering of fabricated information through smart contracts, effective voting, and consensus mechanisms, which can prevent unauthenticated participants from sharing garbage information. We also prove that the proposed solution is secure in the universal composability framework, and further evaluate its performance over an Ethereum-based blockchain platform to demonstrate its utility.

Building Information Modeling (BIM) is envisioned as an indispensable opportunity in the architecture, engineering, and construction (AEC) industries as a revolutionary technology and process. Smart construction relies on BIM for manipulating information flow, data flow, and management flow. Currently, BIM model has been explored mainly for information construction and utilization, but rare works pay efforts to information security, e.g., critical model audit and sensitive model exposure. Moreover, few BIM systems are proposed to chase after upcoming computing paradigms, such as mobile cloud computing, big data, blockchain, and Internet of Things. In this paper, we make the first attempt to propose a novel BIM system model called bcBIM to tackle information security in mobile cloud architectures. More specifically, bcBIM is proposed to facilitate BIM data audit for historical modifications by blockchain in mobile cloud with big data sharing. The proposed bcBIM model can guide the architecture design for further BIM information management system, especially for integrating BIM cloud as a service for further big data sharing. We propose a method of BIM data organization based on blockchains and discuss it based on private and public blockchain. It guarantees to trace, authenticate, and prevent tampering with BIM historical data. At the same time, it can generate a unified format to support future open sharing, data audit, and data provenance.

OBJECTIVES: Oxygen 6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is a significant prognostic biomarker in astrocytomas, especially for temozolomide (TMZ) chemotherapy. This study aimed to preoperatively predict MGMT methylation status based on magnetic resonance imaging (MRI) radiomics and validate its value for evaluation of TMZ chemotherapy effect. METHODS: We retrospectively reviewed a cohort of 105 patients with grade II-IV astrocytomas. Radiomic features were extracted from the tumour and peritumoral oedema habitats on contrast-enhanced T1-weighted images, T2-weighted fluid-attenuated inversion recovery images and apparent diffusion coefficient (ADC) maps. The following radiomics analysis was structured in three phases: feature reduction, signature construction and discrimination statistics. A fusion radiomics signature was finally developed using logistic regression modelling. Predictive performance was compared between the radiomics signature, previously reported clinical factors and ADC parameters. Validation was additionally performed on a time-independent cohort (n = 31). The prognostic value of the signature on overall survival for TMZ chemotherapy was explored using Kaplan Meier estimation. RESULTS: The fusion radiomics signature exhibited supreme power for predicting MGMT promoter methylation, with area under the curve values of 0.925 in the training cohort and 0.902 in the validation cohort. Performance of the radiomics signature surpassed that of clinical factors and ADC parameters. Moreover, the radiomics approach successfully divided patients into high-risk and low-risk groups for overall survival after TMZ chemotherapy (p = 0.03). CONCLUSIONS: The proposed radiomics signature accurately predicted MGMT promoter methylation in patients with astrocytomas, and achieved survival stratification for TMZ chemotherapy, thus providing a preoperative basis for individualised treatment planning. KEY POINTS: • Radiomics using magnetic resonance imaging can preoperatively perform satisfactory prediction of MGMT methylation in grade II-IV astrocytomas. • Habitat-based radiomics can improve efficacy in predicting MGMT methylation status. • Multi-sequence radiomics signature has the power to evaluate TMZ chemotherapy effect.

BackgroundThe diagnosis performance of B-mode ultrasound (US) for focal liver lesions (FLLs) is relatively limited. We aimed to develop a deep convolutional neural network of US (DCNN-US) for aiding radiologists in classification of malignant from benign FLLs.Materials and methodsThis study was conducted in 13 hospitals and finally 2143 patients with 24,343 US images were enrolled. Patients who had non-cystic FLLs with pathological results were enrolled. The FLLs from 11 hospitals were randomly divided into training and internal validations (IV) cohorts with a 4:1 ratio for developing and evaluating DCNN-US. Diagnostic performance of the model was verified using external validation (EV) cohort from another two hospitals. The diagnosis value of DCNN-US was compared with that of contrast enhanced computed tomography (CT)/magnetic resonance image (MRI) and 236 radiologists, respectively.FindingsThe AUC of ModelLBC for FLLs was 0.924 (95% CI: 0.889–0.959) in the EV cohort. The diagnostic sensitivity and specificity of ModelLBC were superior to 15-year skilled radiologists (86.5% vs 76.1%, p = 0.0084 and 85.5% vs 76.9%, p = 0.0051, respectively). Accuracy of ModelLBC was comparable to that of contrast enhanced CT (both 84.7%) but inferior to contrast enhanced MRI (87.9%) for lesions detected by US.InterpretationDCNN-US with high sensitivity and specificity in diagnosing FLLs shows its potential to assist less-experienced radiologists in improving their performance and lowering their dependence on sectional imaging in liver cancer diagnosis.

BACKGROUND: Predicting early recurrence (ER) after radical therapy for HCC patients is critical for the decision of subsequent follow-up and treatment. Radiomic features derived from the medical imaging show great potential to predict prognosis. Here we aim to develop and validate a radiomics nomogram that could predict ER after curative ablation. METHODS: Total 184 HCC patients treated from August 2007 to August 2014 were included in the study and were divided into the training (n = 129) and validation(n = 55) cohorts randomly. The endpoint was recurrence free survival (RFS). A set of 647 radiomics features were extracted from the 3 phases contrast enhanced computed tomography (CECT) images. The minimum redundancy maximum relevance algorithm (MRMRA) was used for feature selection. The least absolute shrinkage and selection operator (LASSO) Cox regression model was used to build a radiomics signature. Recurrence prediction models were built using clinicopathological factors and radiomics signature, and a prognostic nomogram was developed and validated by calibration. RESULTS: Among the four radiomics models, the portal venous phase model obtained the best performance in the validation subgroup (C-index = 0.736 (95%CI:0.726-0.856)). When adding the clinicopathological factors to the models, the portal venous phase combined model also yielded the best predictive performance for training (C-index = 0.792(95%CI:0.727-0.857) and validation (C-index = 0.755(95%CI:0.651-0.860) subgroup. The combined model indicated a more distinct improvement of predictive power than the simple clinical model (ANOVA, P < 0.0001). CONCLUSIONS: This study successfully built a radiomics nomogram that integrated clinicopathological and radiomics features, which can be potentially used to predict ER after curative ablation for HCC patients.